The worst Ebola virus disease outbreak in history ended in 2016 after infecting 28,600 people and killing about 11,300 worldwide.
The outbreak led to urgent action by medical experts across the world to combat this devastating disease; including the setting up of trials of vaccines to stop the disease taking hold.
This global commitment to develop a vaccine against the disease suggested eight options, out of a starting pool of 15 candidates, should be evaluated in clinical trials worldwide by the end of 2015.
Professor Sanjeev Krishna, of St George’s University of London’s Institute for Infection and Immunity, said: “An unprecedented Ebola outbreak showed how it is possible for academics, non-governmental organisations, industry and funders to work effectively together very quickly in times of medical crisis. The results of the trial show how a vaccine could best be used to tackle this terrible disease effectively.
“We need a system of specialists, medical experts and organisers that maintains vigilance against outbreak diseases like Ebola.
“We should continue to improve ways to make, evaluate and deliver vaccines when they are needed, often in parts of the world lacking in infrastructure for diagnosing infections and providing treatments.”
He explained that considering the persistent replication of the vaccine which is called rVSV-?GP-ZEBOV in children and adolescents, further studies investigating lower doses in this population are warranted.
The vaccine contains a non-infectious portion of a gene from the Zaire Ebola virus. The St George’s researchers worked with colleagues on a vaccine trial in Gabon.
In addition, lower vaccine doses should be considered when boosting individuals with pre-existing antibodies to Ebolavirus glycoprotein, a finding that has emerged after the vaccine was tested in a country that has experienced Ebolavirus outbreaks in the past.
The vaccine was one of two being examined as a ‘candidate’ option by the World Health Organisation to identify urgently a vaccine to combat the Ebola virus outbreak in West Africa.
The clinical trial was led by colleagues at University of Tübingen in Germany, coordinated by Professor Peter Kremsner with their partner institute CERMEL in Lambaréné, Gabon.
The Latest on: Ebola vaccine
- Coronavirus: Top scientist who battled COVID-19 says we will never live normally without vaccineon May 11, 2020 at 5:31 pm
A top scientist who fell ill with COVID-19 has said the world will never return to normal unless there is a coronavirus vaccine. Peter Piot, director of the London School of Hygiene & Tropical ...
- Why Human Challenge Trials Will Be Necessary to Get a Coronavirus Vaccineon May 11, 2020 at 3:10 pm
"Is the risk to volunteers too high? Firefighters and physicians take on risk for the social good, as do kidney donors. Over a thousand people have already volunteered to be considered for a challenge ...
- Top scientist who battled COVID-19 says 'we will never ... live normally' without vaccineon May 11, 2020 at 1:44 pm
A top scientist who fell ill with COVID-19 says the world will never return to normal unless there is a coronavirus vaccine.
- Regulators would consider releasing an unapproved coronavirus vaccineon May 9, 2020 at 7:29 am
Anthony Fauci, director of the US National Institute of Allergy and Infectious Disease (NIAID), said a coronavirus vaccine was “on track” to be distributed to the public in 12 to 18 months. Compared ...
- How Ebola Helped Africa Prepare for Coronaviruson May 8, 2020 at 8:00 pm
HIV/Aids, Lassa fever, and tuberculosis are just some of the communicable diseases that African health experts are used to dealing with, and many realized the danger of the coronavirus as soon as they ...
- How Lessons From Ebola Can Help Fight COVID-19on May 8, 2020 at 3:12 am
An infectious disease specialist in Atlanta is drawing on his experiences treating Ebola patients while caring for those with COVID-19.
- Does Inovio Pharmaceuticals Have a Successful Track Record of Developing Vaccines?on May 7, 2020 at 11:46 am
One such stock is Inovio Pharmaceuticals (NASDAQ:INO), which said it developed a vaccine for COVID-19 in February three hours after the genome for COVID-19 was published. As of April 28, the company ...
- Ebola Vaccine Market Research – Industry Analysis, Growth, Size, Share, Trends, Forecast to 2026on May 6, 2020 at 1:21 pm
May 06, 2020 (AB Digital via COMTEX) -- Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the ...
- Medical Student Volunteer in COVID-19 Vaccine Trial Also Tested Ebola Vaccineon April 28, 2020 at 4:08 pm
Sean Doyle, a 31-year-old medical student at Emory University in Georgia, is one of the volunteers getting shots as part of a COVID-19 vaccine trial. While some might be scared of being a human guinea ...
- Med Student Who Volunteered for COVID-19 Vaccine Trial Also Received Experimental Ebola Treatmenton April 28, 2020 at 2:16 pm
Sean Doyle, who is studying to become a doctor at Emory University in Georgia, received the potential Ebola vaccine two years ago by a team of scientists at the university.
via Google News and Bing News